Humana, Inc.

Humana, Inc. has achieved a new 52-week high, reflecting its strong market position in the healthcare services sector. The company has shown a 5.54% stock gain over the past year, with solid financial metrics including a favorable debt-to-equity ratio and a dividend yield of 1.60%.

Humana, Inc. has achieved a new 52-week high, reflecting its strong market position in the healthcare services sector with a market capitalization of USD 32,156 million. The company shows a year-over-year stock performance increase, a solid balance sheet, and a notable return on equity, emphasizing its competitive standing.

Humana, Inc. has achieved a new 52-week high, reflecting its strong market position in the healthcare services sector. The company has shown a modest stock performance increase over the past year, with a solid balance sheet and a dividend yield, indicating its commitment to shareholder returns.

Humana, Inc. has achieved a new 52-week high, reflecting its strong performance in the healthcare sector. The company has a market capitalization of USD 32,156 million, a P/E ratio of 27.00, and a dividend yield of 1.60%. Its financial metrics indicate a solid position in the market.

Humana, Inc. has seen a notable increase in stock performance, with a 7.94% rise on April 7, 2026, reaching an intraday high of USD 203.50. Despite recent gains, the company faces longer-term challenges, including a one-year decline of 22.6%, while maintaining strong fundamentals and competitive positioning in the healthcare sector.

Humana, Inc. has recently adjusted its valuation, with its stock price at $176.95. Over the past year, the company has experienced a notable decline in stock return compared to the S&P 500. Key financial metrics indicate a premium market positioning relative to peers, highlighting competitive dynamics in the healthcare services sector.

Humana, Inc. has reached a new 52-week low, reflecting a difficult year with a significant stock price decline. The company has a market capitalization of USD 32,327 million, a P/E ratio of 27.00, and a dividend yield of 1.26%, indicating mixed financial performance amid industry challenges.

Humana, Inc. has recently adjusted its valuation metrics, reporting a P/E ratio of 27 and an EV to EBITDA of 30.27. The company has faced significant stock performance challenges, with a year-to-date return of -33.46%, contrasting sharply with the S&P 500's performance.

Humana, Inc. has seen a significant increase in its stock price today, contrasting with the S&P 500's modest rise. Despite this uptick, the company has faced challenges over the past month and year, with notable declines in performance metrics. Humana's market capitalization is approximately USD 36 billion.

Humana, Inc. faced a notable stock decline today, reaching an intraday low and reflecting a challenging market environment. Despite a recent net profit report indicating positive momentum, the company's stock has underperformed compared to the S&P 500 over the past year, raising concerns about its valuation metrics.

Humana, Inc. has recently revised its evaluation amid fluctuating market conditions, with its stock showing a slight increase. Over the past year, the company has experienced significant trading activity. Despite some mixed technical indicators, Humana's returns have lagged behind the S&P 500 across various time frames, reflecting ongoing challenges.

Humana, Inc. has seen a notable increase in its stock performance, reaching an intraday high of USD 287.32. While it has outperformed the S&P 500 recently, the company has faced longer-term challenges. Humana reported a net profit of USD 1,789 million in March 2025 and maintains a strong return on equity.